Lutz Hegemann, Novartis president of global health

No­var­tis li­cens­es out leukemia drug as part of new glob­al coali­tion to in­crease ac­cess to can­cer treat­ments

The Union for In­ter­na­tion­al Can­cer Con­trol (UICC) has gath­ered a slate of Big Phar­mas for its new col­lab­o­ra­tion in hopes of in­creas­ing ac­cess to can­cer med­i­cines in low­er in­come coun­tries, UICC an­nounced yes­ter­day.

Dubbed ATOM, or Ac­cess to On­col­o­gy Med­i­cines, the coali­tion in­cludes As­traZeneca, BeiGene, No­var­tis, Bris­tol My­ers Squibb, Roche, Gilead, and Sanofi, among oth­er or­ga­ni­za­tions. The goal of the part­ner­ship is to in­crease gener­ic and biosim­i­lar de­vel­op­ment of can­cer drugs as well as li­cense out es­sen­tial med­i­cines to these coun­tries. The third part of the part­ner­ship in­cludes build­ing up the in­fra­struc­ture to di­ag­nose can­cers and prop­er­ly han­dle can­cer med­i­cines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.